文献速递白血病

TARGET调查:33国慢性髓性白血病真实世界管理现状

TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
PubMed 文献 · Br J Haematol · 2020-03-30

TARGET调查于2017年在线完成,覆盖33个国家614名血液科医生,评估慢性髓性白血病(CML)真实世界管理是否契合国际推荐。调查发现疗效评估与分子学监测存在差距,半数医生未在治疗初12个月每3个月检测,主要障碍为费用;无治疗缓解未被视作主要治疗目标;对持续不良事件管理认知不足。指导委员会提出以医生教育及医院与政府协作提升BCR-ABL检测质量等实用对策。

要点

  • 半数医生未在CML初始治疗12个月内每3个月行分子学检测,费用为主要障碍。
  • 无治疗缓解未被多数医生视作主要治疗目标或影响治疗决策的优先因素。
  • 对持续不良事件的管理认知普遍不足,需加强医生教育与检测质量改进。

核心结论

  • 当前CML管理与国际推荐存在差距,指导委员会提出的实用解决方案有助于弥补这些差距。

研究设计与样本

  • TARGET为在线调查,于2017年完成,覆盖33个国家的1008名受邀血液科医生,共614人完成调查。
  • 由8名国际血液科医生组成的指导委员会讨论结果,识别挑战并制定实用解决方案。

主要发现

  • 在治疗疗效和分子学监测方面识别出差距。
  • 半数医生未在治疗初始12个月内每3个月进行检测,虽知晓应做,但称费用是主要障碍。
  • 无治疗缓解未被视作主要治疗目标或影响治疗决策的优先因素。
  • 对欧洲白血病网(ELN)指南的解读总体可接受,但对持续不良事件管理的认知较差。

关键数值与推荐

  • 指导委员会提出的实用解决方案主要聚焦于加强医生教育与认知,或鼓励医院与政府合作以提升BCR-ABL检测质量。

临床怎么用

  • 应推动CML治疗初12个月内每3个月分子学监测的落实,并解决费用障碍。
  • 需加强医生对持续不良事件管理和无治疗缓解概念的教育与认知。
  • 可通过医院与政府协作提升BCR-ABL检测质量。

局限性

  • 调查于2017年完成,结果可能不代表当前实践。
  • 为在线调查,完成率为614/1008,可能存在应答偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the availability of guidelines for the management of chronic myeloid leukaemia (CML), various issues may prevent their successful implementation. The TARGET survey examined real-world management of CML patients compared with international recommendations. This online survey was completed in 2017. Results were discussed by a Steering Committee (SC) of eight international haematologists, challenges were identified and practical solutions developed. Of the 1008 haematologists invited (33 countries), 614 completed the survey. Gaps regarding treatment efficacy and molecular monitoring were identified. Half of the physicians did not perform three-monthly testing of during the initial 12 months of treatment, citing cost as the major barrier, although they know it should be done. Treatment-free remission was not considered a primary treatment goal or as a priority factor influencing treatment decisions. European Leukemia Net guidelines interpretation was generally acceptable, but awareness regarding management of persistent adverse events was poor. Practical solutions proposed by the SC were mostly focused on enhancing physician education and awareness, or encouraging hospitals to work with the government, in order to improve the quality of BCR-ABL testing. Gaps in current CML management were identified compared with international recommendations, which the proposed practical solutions would help to address.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Turkina A, Wang J, Mathews V, et al. TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. Br J Haematol. 2020. PMID: 32227648. doi:10.1111/bjh.16599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。